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Abstract
Background: The standard treatment for patients with advanced transitional cell carcinoma of the bladder is platin
based chemotherapy. Only approximately 50% of the patients respond to chemotherapy. Therefore, molecular
predictive markers for identification of chemotherapy sensitive subgroups of patients are highly needed. We
selected the transcription factor TFAP2a from a previously identified gene expression signature for chemotherapy
response.
Methods: TFAP2a expression and localization was assessed by immunohistochemistry using a tissue microarray
(TMA) containing 282 bladder cancer tumors from patients with locally advanced (pT2-T4b and N1-3) or metastatic
(M1) disease. All patients had received cisplatin containing chemotherapy. Furthermore, QPCR analysis of three
TFAP2a isoforms was performed on tumor specimens of advanced muscle invasive bladder cancers (T2-4). Using
the bladder cell lines T24 and SW780 the relation of TFAP2a and cisplatin and gemcitabine sensitivity as well as
cell proliferation was examined using siRNA directed TFAP2a knockdown.
Results: TFAP2a protein expression was analyzed on a TMA with cores from 282 advanced bladder cancer tumors
from patients treated with cisplatin based combinational chemotherapy. TFAP2a was identified as a strong
independent predictive marker for a good response and survival after cisplatin-containing chemotherapy in
patients with advanced bladder cancer. Strong TFAP2a nuclear and cytoplasmic staining predicted good response
to chemotherapy in patients with lymph node metastasis, whereas weak TFAP2a nuclear staining predicted good
response in patients without lymph node metastasis. In vitro studies showed that siRNA mediated knockdown of
TFAP2a increased the proliferation of SW780 cells and rendered the cells less sensitive to cisplatin and
gemcitabine. In contrast to that T24 bladder cells with mutated p53 showed to be more drug sensitive upon
TFAP2a depletion.
Conclusions: High levels of nuclear and cytoplasmic TFAP2a protein were a predictor of increased overall survival
and progression free survival in patients with advanced bladder cancer treated with cisplatin based chemotherapy.
TFAP2a knockdown increased the proliferation of the SW780 bladder cells and reduced cisplatin and gemcitabine
induced cell death. The inverse effect was observed in the TP53 mutated T24 cell line where TFAP2a silencing
augmented cisplatin and gemcitabine sensitivity and did not stimulate proliferation.
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Background
Bladder cancer is the fifth most common malignancy in
Europe and the fourth most common malignancy in the
United States. The most prevalent histological type is
transitional cell carcinoma (TCC), which constitutes up
to 95% of the malignancies of the bladder. About 30% of
TCC’s display a solid, invasive growth pattern, being
either locally advanced (pT3a, pT3b, pT4 and/or pN1,
pN2, pN3 M0) or metastatic (M1) at the time of diagnosis
or at later visits [1]. The response rate to chemotherapy is
only approximately 50% [2]. Presently, there are two
standard chemotherapeutic regimens: MVAC (metho-
trexate, vinblastine, doxorubicin, and cisplatin) or GC
(gemcitabine and cisplatin). Median survival is 14 to
15 months, and 5-year overall survival rate is between
13% and 15% [3]. Although the gemcitabine and cisplatin
combination has a significantly better toxicity profile,
both regimens still carries risk for significant toxicity and
toxic deaths [4] and a substantial fraction of patients will
suffer from adverse reactions without achieving any ben-
efit. It is therefore of utmost importance to be able to dis-
criminate between responders and non-responders for
improved selection of patients to chemotherapy and to
improve the individual patient’s quality of life. A molecu-
lar signature for chemo-resistance, based on microarray
profiling of cancer specimens has been described for
locally advanced and/or metastatic bladder cancer [5].
BIRC5 (survivin) and BSG (emmprin) were validated as
independent predictive markers for response and survival
after cisplatin-containing chemotherapy by immunohis-
tochemistry in an independent material of 124 patients
with locally advanced (T4b and N2-3) or metastatic (M1)
disease [5]. In the present study we investigated another
interesting molecule from this gene expression signature,
the transcription factor Activator Protein TFAP2a.
TFAP2a belongs to the TFAP2 family of transcription
factors that in humans and mice consist of five members,
TFAP2a, TFAP2b, TFAP2g, TFAP2δ and TFAP2ε.
Orthologs show a similarity between 60 and 99% at the
amino-acid level. The TFAP2 family is characterized by
having a highly conserved helix-span-helix dimerization
motif at the carboxyl terminus together with a central
basic region and a less conserved proline/glutamine rich
domain at the amino terminus. The helix-span-helix
domain facilitates homo and heterodimerization between
the TFAP2 members. Once dimerized, the helix-span-
helix motif and the neighboring basic domain facilitate
DNA binding and the N-terminal proline/glutamine-rich
domain mediates transactivation. The TFAP2 family
members participate in the regulation of many signaling
pathways and are essential during embryogenesis and
development. TFAP2 proteins participate in tumorigen-
esis through regulation of neoplasia associated genes
such as P21, Rb, TP53, ERa, BCL2, cKIT, MMP-2, E-cad-
herin and c-myc (reviewed in [6,7]). TFAP2a knockout
mice are not viable and have severe ventral body wall clo-
sure defects (thoracoabdominoschisis)[8]. Currently
many studies have linked deregulated TFAP2a activity to
malignant transformation. The TFAP2a gene locus at
6p22 is frequently lost in various cancers [9]. Lost or
decreased TFAP2a expression has been identified in
human cancers of the breast, colon, prostate, ovary and
brain [10-15] suggesting TFAP2a to be a tumor suppres-
sor gene. Immunohistochemical analysis demonstrated a
correlation between decreased TFAP2a expression and
advanced colon adenocarcinomas [11]. In breast cancer,
low nuclear TFAP2a expression is associated with disease
progression and elevated metastatic capability [12].
Furthermore, reduced TFAP2a expression predicted ele-
vated risk of recurrent disease in breast cancer [16].
Moreover, re-expression of TFAP2a in metastatic mela-
noma cells decreased their tumorigenity and inhibited
their metastatic potential in nude mice [17]. So far the
importance of TFAP2a in transitional cell carcinomas of
the bladder has not been described. In the present study,
we showed that high levels of nuclear and cytoplasmic
TFAP2a protein were associated with increased overall
survival and progression free survival of patients with
lymph node positive advanced bladder cancer after cis-
platin based chemotherapy. Furthermore, we showed that
siRNA mediated knockdown of TFAP2a stimulated pro-
liferation of the SW780 bladder cell line along with
decreased cisplatin and gemcitabine sensitivity.
Methods
Archival formalin-fixed paraffin embedded (FFPE) tissues
of cystectomy specimens were derived from a previously
reported Phase III, multicenter randomized control trial of
two different adjuvant chemotherapy regimens, AUO-AB
05/95 conducted by the Arbeitsgemeinschaft Urologische
Onkologien (AUO) collaborative group of the Federal
Republic of Germany [18,19]. The clinicopathological
characteristics of all patients were reviewed by one surgical
pathologist (A.H.). Tumor staging was performed accord-
ing to the criteria of the International Union against
Cancer (UICC). Representative haematoxylin- and eosin-
stained (HE) slides of formalin-fixed and paraffin-
embedded tissue blocks obtained at cystectomy where
reviewed and the tumor area was marked. Tissue microar-
rays (TMA) where constructed by obtaining a 1.5 mm
punch-biopsy from each tumor. TMA construction was
done as described previously [20]. The TMAs were stained
with HE and were reviewed for the presence of representa-
tive tumor tissue by one surgical pathologist. The study
was approved by the local ethical committee of the
University Regensburg.
Nordentoft et al. BMC Cancer 2011, 11:135
http://www.biomedcentral.com/1471-2407/11/135
Page 2 of 11
Expression Plasmids
Plasmids of the human TFAP2a isoform 2 GenBank
[NM_001032280] and 3 GenBank [NM_001042425]:
pcDNA3.1/V5-His-TFAP2a v2 and pcDNA3.1/V5-His-
TFAP2a v3 were generated by PCR amplification
(Expand High Fidelity PCR System (Roche)) of bladder
cancer patient cDNA as template using the primer pairs:
5’-GCCACCATGTTAGTTCACAGTTTTTCAGCC-3’,
5’-CTTTCTGTGCTTCTCCTCTTTGTCACTG-3’ and
5’- GAGCCGCGATGTCCATACTTGCC -3’, 5’-CTTT
CTGTGCTTCTCCTCTTTGTCACTG-3’ respectively
and cloned into the pcDNA3.1/V5-His©TOPO©TA
expression vector (Invitrogen) following manufactures
instructions.TFAP2a isoform 1 GenBank[NM_003220]
was generated by sub-cloning from pcDNA3.1/V5-His-
TFAP2a v3 using primer pair 5’-CCACCATGCTTTG-
GAAATTGACGGATAATATCAAGTACGAGGACTG-
CGAGGACCGTCAC-3’ and 5’-CTTTCTGTGCTTC
TCCTCTTTGTCACTG-3’. The PCR product was subse-
quently cloned as described above.
Western blotting
Whole cell protein lysates from COS7, T24 and SW780
were collected using a cell scraper and lysed in RIPA buf-
fer (50 mM TRIS pH 7.5, 150 mM NaCl, 1% NP40, and
0.5% Deoxycholic Acid, sodium salt) supplemented with
complete protease inhibitor cocktail (Boehringer Man-
nheim). Protein concentration was determined using Brad-
ford reagent (BioRad laboratories, HerculesCA, USA). A
25 μg sample was resolved by SDS-PAGE (12% Tris-HCl,
Invitrogen). Proteins were transferred to PVDF membrane
(Millipore) and blocked overnight with 3% w/v skimmed
milk powder in PBS buffer supplemented with 0.05%
Tween-20. Membranes were probed with primary anti-
TFAP2a mouse IgG (Abcam, ab18112 1:500) and subse-
quently, secondary horseradish peroxidase-conjugaed goat
anti-mouse (Dako Cytomation 1:5000). The immunoreac-
tive bands were visualized using ECL plus (Amersham
Biosciences) and UVP ChemiDoc-It, Imaging system
(UVP Inc.)
Cell Culture
Bladder cell lines T24 and SW780 were obtained from
American Type Culture Collection (ATCC-LGC stan-
dards, Borås, Sweden), were re-authenticated via STR
analysis using the Cell-ID-system (G9500, Promega,
Nacka, Sweden), products were analysed on an Applied-
Biosystems3130 Genetic Analyser. No mycoplasma con-
tamination was detected using nested PCR-based myco-
plasma detection. COS-7 cells (green monkey) were
cultured in RPMI 1640 and T24 (P53 Y126*, HRAS
G12V) and SW780 bladder cells in DMEM with L-gluta-
mine (Gibco, Invitrogen Corporation, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum
(Gibco), 100 U/ml penicillin (Gibco) and 100 U/ml
streptomycin (Gibco) and maintained in a humidified
atmosphere at 37 °C and 5% CO2.
Transient transfection
The day prior to transfection 5 × 105 COS-7, 6 × 105 T24,
6 × 105 SW780 cells in T25 culture flasks (5 ml culture
medium), 28 × 103T24, 42 × 103 SW780 cells in 24-well
plates (500 μl culture medium), 4 × 103 T24, 6 × 103
SW780 cells in 96-well (100 μl culture medium). Plasmid
transfections were performed using FuGENE 6 (Roche)
and siRNA transfections were performed using Lipofecta-
min 2000 both following the manufacturer’s instructions.
TFAP2a specific siRNA was obtained from Ambion (ABI;
Foster City, CA)(Cat# s14003). Non-targeting siRNA was
obtained from Dharmacon as Non-TARGET #2 siCON-
TROL (Cat# D-001208-14-20).
Isolation of RNA
T24 and SW780 RNA was isolated from 6-well and 24-well
plates using RNeasy spin columns (Qiagen, Hilden,
Germany), as recommended by the manufacturer. RNA was
quantified by measuring absorbance at 260 and 280 nm.
Cell Proliferation Assay
Cell proliferation was measured using the CyQUANT cell
proliferation assay (Invitrogen) according to the manufac-
turer’s instructions. Fluorescence measurements were
made using a microplate reader (Labsystems Multiscan
MCC/340) with excitation at 485 nm and emission detec-
tion at 530 nm.
Cell viability assay
The viability of sub-confluent cells was analyzed by 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction assay. The assay was performed in 96
well plates seeding 4000-6000 cell/well in 200 μl. After
24 h 100 μl culture medium was carefully removed and
25 μl MTT solution was added (1 g MTT (Sigma M5655)
dissolved in 200 mL D-PBS.) and stored shielded from
light 1.5 h at 37°C and then 100 μl solubilization (50%
dimethylformamide, 20% SDS) buffer was added and left
protected from light ON. Readout was done using a
microplate reader (Labsystems Multiscan MCC/340) at
540 nm. Absorbance at 692 nm was used as reference.
Real-time RT-PCR
One μg of total RNA was used for cDNA synthesis with
random hexamer primers using the SuperScript® II
Reverse Transcriptase (Invitrogen Calsbad, CA, USA)
according to the manufacturer’s instructions. Total RNA
at 10-50 ng per 10 uL of reaction mixture was used for
measurement of the target mRNA. The real-time RT-PCR
assay was performed using the ABI 7500 FAST machine
Nordentoft et al. BMC Cancer 2011, 11:135
http://www.biomedcentral.com/1471-2407/11/135
Page 3 of 11
(ABI;Foster City, CA). 10 ul real-time RT-PCR reactions
consists of 5 ul 2× TaqMan® FAST Universal Master Mix
(P/N 43660783, ABI; Foster City, CA), 0.5 ul 20 × Taq-
Man® Assay/probe (ABI;Foster City, CA)) and cDNA
equivalent to 10-50 ng of total RNA in 4.5 ul H2O. Ther-
mal FAST cycle program was: 20 s at 95°C followed by 40
cycles of 3 s at 95°C and 30 s at 60°C. Reactions were set
up in triplicate for each sample, and gene expressions
were normalized to eukaryotic Ubiquitin C using SYBR
GREEN PCR Master Mix (Applied Biosystems) and pri-
mers 5’-GATTTGGGTCGCGGTTCTT-3’, 5’-TGCCTTG
ACATTCTCGATGGT-3’ [21]. All assays were carried out
in 96-well format plates covered with optical adhesive
cover (P/N 4346906 and P/N 4311971 ABI, Foster
City, CA). We used the 2-ΔΔCT method to calculate
the relative gene expression. TaqMan® Assays used
were: Hs01029410_m1 (TFAP2a isoform 1,2 and 3);
Hs00231461_m1 (TFAP2a isoform); Hs01033609_m1
(TFAP2a isoform).
Growth curves via RT-CES system (RTCA)
The T24 or SW780 cells were harvested and transferred
into 16-well DP or 96-well SP E-Plates of the RTCA sys-
tem, which contain electrodes integrated into the bot-
tom surfaces of each well that measure cell index based
on impedance using the RT-CES system (ACEA Bios-
ciences, San Diego, CA, USA. This technology has
recently been acquired by Roche Applied Science and is
being marketed under the name xcelligence System).
Changes in cell status such as cell number, viability and
adherence were monitored in real time and quantified
by detecting sensor electrical impedance. Cell index cor-
relates with the number of cells attached to the bottom
of the plate. For the experiments reported here, the
number of cells added to each well varied from 4000 to
6000 per well with a total volume of 200 μl of media.
Immunohistochemistry
Immunohistochemical analysis of FFPE bladder tissue
sections (4 μm) and tissue microarray sections were per-
formed essentially as described in [22]. The primary
antibody against TFAP2a was ab18112 (mouse mono-
clonal, dilution 1:40, Abcam). Core biopsies of the TMA
were either evaluated according to cytoplasmic staining
(weak or strong intensity) or nuclear staining (weak or
strong intensity). The TMA’s were scored blinded and
independently by two observers. In case of disagree-
ment, the core was reevaluated and consensus was
reached.
Statistical analysis
All data calculations were done using the STATA statis-
tical software (version 10).
Results
Expression of the individual variants of TFAP2a in
advanced bladder cancer specimens
A real-time Q-PCR analysis was performed using cDNA
from 10 tumor specimens of advanced muscle invasive
bladder cancer (T2-4) to analyze the expression of the
TFAP2a transcript variants. The analysis confirmed that
all three variants of TFAP2a were present in all of the
10 tested bladder tumors (Figure 1A). The largest iso-
form TFAP2a-1 was most abundantly expressed com-
pared to TFAP2a isoform 2 and 3. The mRNA level of
TFAP2a isoform 1 was approximately 8 and 16 fold
higher than isoform 2 and 3 respectively (p < 0.005).
There is no statistical difference in expression levels
between the mRNA level of isoform 2 and 3.
TFAP2a expression in bladder carcinomas
To assess the biological significance of TFAP2a expres-
sion in bladder tumors, we evaluated the expression
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Figure 1 Expression of TFAP2a isoforms . (A) Expression of
TFAP2a isoform 1, 2 and 3 in advanced muscle invasive bladder
cancer (T2-4) were determined using real-time Q-PCR. Analysis was
performed on cDNA from 10 tumor specimens and each bar
represents the mean from the 10 samples.(B) COS-7 cells were
transiently transfected with empty pcDNA3.1/V5-His vector (lane 2,
6), pcDNA3.1/V5-His-TFAP2a isoform 1(lane 3, 7), isoform 2 (lane 4,
8) and isoform 3 (lane 5, 9). Western blot of 30 μg total protein
lysate from non-transfected HU609 bladder cells (lane 1) and COS-7
transfected cells (lane 2-9) 48 h post transfection probed with anti
TFAP2a antibody (lane 1-5) or anti-V5 antibody (lane 6-9).
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using a TMA containing tumors from 282 patients with
advanced bladder cancer with full clinical annotation
(Table 1). The antibody specificity was tested success-
fully using western blots on total protein cell lysates
(Figure 1B). Protein extracts of cell lysates from COS-7
cells transiently transfected with constructs containing
one of the three different variants of TFAP2a isoforms
1-3 were used to evaluate the specificity of the antibo-
dies against TFAP2a. The antibody detects all three iso-
form (lane 3-5) variants of the protein. The predicted
MW of TFAP2a is 52 KDa in agreement with a slightly
denser band detected due to the fusion of the V5 tag of
the pcDNA3.1 cloning vector. The endogenous TFAP2a
protein is seen below the fusion protein (lane 1-5). The
TMA stained for TFAP2a yielded kappa values of ( =
0.75 cytoplasmic expression) and ( = 0.68 nucleic
expression) between two observers, examples of typical
staining patterns are shown in Figure 2. Kaplan-Meier
survival analysis using all samples on the TMA showed
no statistical association between overall survival or pro-
gression free survival, and cytoplasmic or nuclear
TFAP2a staining. However, Kaplan-Meier survival ana-
lysis restricted to patient samples with lymph node
invasion showed that both strong nuclear and cytoplas-
mic staining correlated with increased overall survival (p
= 0.026 and p = 0.002 respectively(Figure 3A,B) and
progression free survival (p = 0.027 and p = 0.002
respectively; Figure 3C,D). Interestingly, analysis of the
samples without lymph node invasion showed an inverse
correlation for the nuclear staining. Low nuclear
TFAP2a staining was associated with increased overall
survival rate (p = 0.048; Figure 3E). The cytoplasmic
staining showed no correlation to outcome for the non
lymph node invasive group (p = 0.57; Figure 3F).
Cisplatin and Gemcitabine sensitivity of bladder Cancer
cell lines
Studies of breast and colon cell lines show improved drug
sensitivity of cells strongly expressing TFAP2a [11,12].
Furthermore, TFAP2a mediates its growth inhibition
both directly through TP53 interaction and indepen-
dently of TP53. In addition, TFAP2a binds directly to
TP53 and stimulates p21 expression [23]. As our immu-
nohistochemical analysis demonstrated decreased chemo
sensitivity of bladder cancer patients with lymph node
invasion having low TFAP2a expression we investigated
if TFAP2a silencing would render bladder cancer cells
less prone to chemotherapy drugs. The TP53 wild type
bladder cancer cell line SW780 and the TP53 mutated
bladder cancer cell line T24 were chosen to investigate
the role of TFAP2a in chemo sensitivity. IC50 values of
T24 and SW780 upon Cisplatin and Gemcitabine treat-
ment were determined by an MTT viability assay (Figure
4ABCD). For Cisplatin the IC50(48 h) was around 10 μM
for T24 and 15 μM for SW780. Gemcitabine had an IC50
(48 h) of 15 μM for T24 and 50 μM for SW780. To verify
the drug response we monitored the effect on cell prolif-
eration in real time during drug incubation (Figure 4).
Cisplatin was added after 24 h affecting the cells in a
time period between 40-60 hours post-addition. For the
T24 cells cisplatin concentration of 4 μM or more inhibit
growth (the max cell index decreased, Figure 4E). At 72 h
that corresponded to the MTT measurement the cell
index of the 10 μM growth curve is 2.1 compared to 4.4
for the control curve without cisplatin. This approxi-
mately 50% reduction showed that the decreased surface
area of the T24 cell population roughly corresponded to
the viability readout. SW780 did not show the same asso-
ciation, but in agreement with the viability assay cisplatin
inhibited cell growth substantially from 8 μM and 16 μM
decreased growth heavily within the chosen 72 time
window (Figure 4F).
TFAP2a depletion decreased chemotherapy sensitivity in
TP53 WT cells
T24 and SW780 cells were transfected with siRNA target-
ing TFAP2a transcript, yielding a 70% knock down 48 h
Table 1 Patient Characteristics
Tumor category
pTis7pT1 pN+ 8(2.9)
pT2 pN0 2(0.7)
pT2 pN+ 34
(12.2)
pT3 pN0 95
(34.2)
pT3 pN+ 89
(32.0)
pT4a pN0 23(8.3)
pT4a pN+ 27(9.7)
*
Age 61.3(28.8-79.2)
Sex
Male 221
(78)
Female 61(22)
Nodal Status
pN0 124
(44)
pN+ 158
(56)
Survival
parameters
Progression-free
survival
Overall
Survival
pN0 32.9 34.9
pN+ 21.5 24.5
*The stage was missing on four patients.
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Figure 2 Immunohistochemistry of bladder cancer tissue with antibody against TFAP2a. TFAP2a immunoreactivity of muscle invasive
bladder cancer tumors. A and D: Negative stain of nucleus and cytoplasm at 5 and 40 fold objective magnification, respectively. B and E:
Negative stain of nucleus and positive stain of cytoplasm (5× and 40×, respectively). C and F: Positive stain of nucleus and cytoplasm (5× and
40×, respectively).
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Figure 3 The relationship between TFAP2a staining and survival after chemotherapy. TFAP2a immunoreactivity and overall survival (OS)
rates and progression free survival (PFS). A and B: separation of OS (overall survival) curves based on TFAP2a nuclear and cytoplasmic staining in
the lymph node invasive group, respectively. C and D: separation of PFS curves based on TFAP2a nuclear and cytoplasmic staining in the lymph
node invasive group, respectively. C and F: separation of OS curves based on TFAP2a nuclear and cytoplasmic staining in the non lymph node
invasive group, respectively. Red curves are high TFAP2a staining and blue curves are low TFAP2a staining.
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post transfection (Figure 5AB). In order to perform the
drug incubation without the cells getting too confluent the
T24 and SW780 cells were first transfected in T25 culture
flask and subsequently after 48 h incubation the cells were
harvested and reseeded in 96 well plates. This extended
time period did not have an impact on the knock down
(data not shown). Next we added cisplatinor gemcitabine
and incubated for 48 h followed by viability analysis (Fig-
ure 5C-F). TFAP2a silencing rendered SW780 less sensi-
tive against cisplatin and gemcitabine induced cell death
(Figure 5D and 5F), however in T24 cells the opposite
effect was observed (Figure 5C and 5E).
TFAP2a affected cell proliferation
Visual inspection of the TFAP2a siRNA transfected
SW780 cells showed a higher cell population compared
to the SW780 cells transfected with siRNA control. To
investigate the effect of TFAP2a siRNA knockdown on
proliferation we performed real time proliferation analy-
sis (Figure 6A and 5B). The real time proliferation mon-
itoring of T24 showed no difference between the
TFAP2a siRNA transfected and the siRNA control
(Figure 6A) and the addition of cisplatin after 24 h did
not change the proliferation rate either. The TFAP2a
siRNA transfected SW780 cells however were significant
proliferating faster than the siRNA control (Figure 6B).
Addition of cisplatin after 24 h decreased the prolifera-
tion rate, especially for the TFAP2a siRNA knockdown.
In conclusion TFAP2a downregulation stimulated pro-
liferation of SW780 cell but not proliferation of T24
cells. Proliferation studies using a CyQuant proliferation
assay confirmed these results (Figure 6C and 6D).
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 2 4 6 8 10 20 40
Vi
ab
ili
ty
Cisplatin (µM)
T24
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 1 2 3 4 5 7.5 10 15 20 25
Vi
ab
ili
ty
Cisplatin (µM)
SW780
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 1 5 10 15 20 25 50 100 1000
Vi
ab
ili
ty
Gemcitabine (nM)
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 5 10 15 20 25 50 100
Vi
ab
ili
ty
Gemcitabine (nM)
D
A
C
B
FE
0
1
2
3
4
5
6
7
0 20 40 60 80
Ce
ll 
In
de
x 
(T
24
)
Time (h)
0µM cisplatin 1µM cisplatin 2µM cisplatin
4µM cisplatin 6µM cisplatin 8µM cisplatin
10µM cisplatin 16µM cisplatin
0
1
2
3
0 20 40 60 80
Ce
ll 
In
de
x 
(S
W
78
0)
Time (h)
0µM cisplatin 1µM cisplatin 2µM cisplatin
4µM cisplatin 6µM cisplatin 8µM cisplatin
10µM cisplatin 16µM cisplatin
Figure 4 Single agent dose-dependent cytotoxicity induced by cisplatin or gemcitabine. Human bladder cancer cells T24 (A,C) and SW780
(B,D) were seeded in 96 well plates and treatment with the indicated cisplatin or gemcitabine concentration started 24 h after seeding and
continued for 48 h. Cell viability was assessed with MTT-assay. Each drug concentration was tested in six individual wells. Real time growth
curves monitoring was performed with the RT-CES (RTCA) system. The T24 or SW780 cells were seeded into 16-well or 96-well E-Plates, which
contain electrodes integrated into the bottom surfaces of each well that measure cell index based on impedance. Cell index correlates with the
area of cells attached to the bottom of the plate. Cisplatin (E) or gemcitabine (F) at the indicated concentration was added 24 h after seeding.
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Discussion
Studies investigating TFAP2a expression in human can-
cers show a correlation between reduced nuclear expres-
sion of TFAP2a and shorter recurrence-free survival and
aggressive clinicopathological features in colon cancer
[11], breast cancer [16], ovarian cancer [13] and melanoma
[24]. Several in vitro studies demonstrated that TFAP2a
has an inhibitory effect on cell proliferation and tumori-
genesis and proposed that TFAP2a has a tumor suppres-
sive effect in malignancies, although articles with opposing
conclusions also have been published [7]. A large breast
cancer study with immunohistochemical detection of
TFAP2a revealed that a reduced level of TFAP2a in the
nucleus and/or a shift of the protein to the cytoplasm may
predict a shorter recurrence-free survival and breast
cancer-related survival [7]. The observed correlation
between high nuclear TFAP2a staining and decreased
overall survival rate for the non lymph node invasive sub-
group is in agreement with a breast cancer study from
Finland that demonstrated that particular for lymph node
positive patients low nuclear TFAP2a expression is asso-
ciated with disease progression and elevated metastatic
capability [25]. Reduced TFAP2a expression also pre-
dicted elevated risk of recurrent disease in breast cancer
[16]. A study of human melanomas showed that high level
of TFAP2a expression in the cytoplasm relative to the
nucleus correlates with poor prognosis. The loss of nuclear
TFAP2a expression was associated with malignant trans-
formation and progression of melanoma, indicating that
translocation of TFAP2a from the cytoplasm to the
nucleus may be disrupted during melanoma progression.
Thus it seems that the major deficiency in TFAP2a
activity in metastatic melanoma is the loss of nuclear
translocation. This could be due to modifications in the
nuclear-pore complexes or in the activity of the transport
receptors (karyopherines/importins/exportins) or changes
of the TFAP2a protein itself. In our study, both low
nuclear and cytoplasmic expression predicted poor out-
come, suggesting that decrease of TFAP2a transcription/
translation or increased turnover rate are a more likely
course than translocation in the case of bladder cancer.
For the group of patients without lymph node invasion the
association was shifted, high nuclear staining was asso-
ciated with decreased survival time. Although the correla-
tion is not highly significant the difference from the lymph
node invasive group is striking. There is no other study
analyzing the TFAP2a staining in an isolated group of
patients without lymph node invasion. The results of the
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Figure 5 Cisplatin sensitivity of TFAP2a silenced T24 and SW780. A and B: Transfection of 10-50 nM TFAP2a siRNA or control siRNA in T24
and SW780 cells, respectively. Real-time RT-PCR was used to determine the relative TFAP2a mRNA levels 48 h post transfektion. C and D:
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TFAP2a staining analysis raised the question if the
decreased chemo sensitivity of bladder cancer patients
with lymph node invasion having low TFAP2a staining is
due to depletion of TFAP2a or deregulation of a down-
stream target. We performed knock down experiments in
bladder cell lines and subsequently measured their sensi-
tivity against cisplatin and gemcitabine. Previous studies
have shown that the tumor suppressor activity of TFAP2a
is mediated through a direct interaction with TP53.
Furthermore, TFAP2a induces TP53 dependent p21 tran-
scriptional activation. This supports the observed ability of
TFAP2a to induce G1 and G2 cell cycle arrest in TP53+/+
but not in TP53-/- HCT116 colon cells [23]. In contrast to
this, a study with breast cancer cell lines demonstrated
that TFAP2a down regulation decreases chemosensitivity
irrespective of their TP53 status [26]. In light of these
observations, we decided to use a TP53 mutated and a
TP53 wild type bladder cell line to conduct functional
chemosensitivity studies. We chose the T24 (TP53
homozygous Y126*) and the SW780 TP53 wild type line,
both having approximately the same dose response profile
of cisplatin and gemcitabine making them appropriate to
compare. We showed that TFAP2a silencing rendered
SW780 less sensitive against cisplatin and gemcitabine
induced cell death and potentiated the cell death of T24
cells. Moreover, we found that TFAP2a down regulation
stimulated proliferation of SW780 cell and did not change
the proliferation rate of T24 cells. The SW780 cell line
metastasizes to regional lymph nodes in nude mice tumor
transplants, corresponding to the clinical findings in
lymph node positive patients [27,28]. In contrast, TFAP2a
silencing augments cisplatin and gemcitabine sensitivity
and did not stimulate proliferation in the TP53 mutated
and non-tumorigenic T24 bladder cell line, corresponding
to clinical findings in lymph node negative patients. As
mammalian cell terminal differentiate they undergo cell
cycle arrest exiting from the cell cycle. TFAP2a mediates
its role as a differentiation associated transcription factor
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through positive regulation of p21 thereby negatively regu-
lating the cell cycle. TFAP2a induces expression of p21.
The p21 promoter contains a TFAP2a binding site located
at -103 and -95 where TFAP2a binds directly and stimu-
late expression [29]. In addition TFAP2a targets the p21
promoter in the p53 binding region at -2250, however
only in the presence of p53 in agreement with TFAP2a
has been shown to bind P53 in vivo and in vitro [23,30].
Furthermore TFAP2a induces p21 dependent P53 expres-
sion corroborating the observed ability of TFAP2a to
induce G1 and G2 cell cycle arrest [23,31]. The explana-
tion for the aberrant chemosensitivity of TFAP2a silenced
T24 and SW780 could therefore be due to deregulation of
the p53/p21 pathway in T24. For SW780, TFAP2a knock-
down may suppress p53/p21 activation because TFAP2a
is a positive regulate of p53/p21 expression. This potenti-
ates the effect of cisplatin and gemcitabine as well as relief
part of the suppression mediated by p53/p21 on the cell
cycle. Taken together, our findings in T24 and SW780
cells may suggest that TFAP2a down regulation in bladder
cells decreased cisplatin and gemcitabine sensitivity in a
p53/p21 dependent manner. This is in line with studies
showing that knock down of the TFAP2a expression in
breast cancer and colon cancer cell lines resulted in signif-
icant reduction in chemotherapy-induced apoptosis
[26,32]. In non-small cell lung cancer, expression of
p53 and p21(Waf1) in mediastinal lymph node specimens
were significantly related to the response to platinum che-
motherapy [33]. Moreover, overexpression of TFAP2a
expression in a breast cancer cell line augmented
increased chemosensitivity and induced endogenous
TFAP2a protein levels in a posttranscriptional way [26].
Within our study, re-introduction of TFAP2a in T24 and
SW780 was performed by transient and stable transfec-
tion, Transient transfection was very low (<20%) as moni-
tored by QPCR/WB and the selected clones seem to loose
TFAP2a as no increased in transcript was measured
(QPCR) compared to the mock transfected. In the litera-
ture, re-introduction of TFAP2a into TFAP2a-negative
SW480 colon cancer cells stimulates expression of E-cad-
herin and down regulation of the MMP-9 expression and
leads to dramatic loss of cellular invasive potential in vitro.
Interestingly, node positive colorectal cancers showed sig-
nificant losses for p21 and E-cadherin compared to node
negative cancer [34]. TFAP2a directly binds to the promo-
ter of E-cadherin, where it has been previously reported to
act as a transcriptional activator [35]. High E-cadherin
expression has been reported to increase cisplatin and
gemcitabine sensitivity in pancreatic cancer [36]. Further-
more stable transfectants expressing TFAP2a in the
SW480 cell line significantly inhibited their growth in an
orthotopic animal model [35]. Previous studies have also
demonstrated that re-expression of TFAP2a in SW480
cells resulted in an inhibition of colony formation in vitro
and upregulation of p21Waf1/Cip1[31].
Conclusions
In this study we demonstrated that high levels of
nuclear and cytoplasmic TFAP2a protein was a predic-
tor of improved overall survival and progression free
survival of patients with locally advanced bladder cancer
undergoing cisplatin based chemotherapy treatment
when focusing on the lymph node invasive subgroup. In
contrast, high nuclear TFAP2a staining was associated
with decreased overall survival rate for the patients
without lymph node metastases. Moreover, siRNA direc-
ted knock down of TFAP2a stimulated proliferation of
SW780 bladder cells and decreased their cisplatin and
gemcitabine sensitivity. On the contrary, TFAP2a silen-
cing potentiated cisplatin and gemcitabine sensitivity
and did not stimulate proliferation in the TP53 mutated
T24 bladder cell line. Future studies are needed to
further validate the predictive potential of TFAP2a
expression in bladder cancer. Currently, we are collect-
ing bladder tumor samples (locally advanced T3-4, N1-3
and/or metastatic M1) from patients that have been
treated with cisplatin based chemotherapy and which
have been characterized according to the RECIST
response criteria. This cohort will be used to evaluate if
TFAP2a staining and expression are predictive for cis-
platin response in addition to survival.
Acknowledgements
We would like to acknowledge Michael Stöckle Department of Urology,
Saarland University, Homburg/Saar, Germany for involvement in the clinical
trial. We thank Pamela Celis, Susanne Bruun, GitteHøj, Lisbet Kjeldsen and
Rudolf Jung for excellent technical assistance.
Grant support: The John and Birthe Meyer Foundation; Fritz, Georg, and
Marie Cecilie Glud’s Foundation; The Oticon Foundation; The University of
Aarhus; The Danish cancer foundation
Author details
1Molecular Diagnostic Laboratory, Department of Molecular Medicine, Aarhus
University Hospital, Aarhus, Denmark. 2Institute of Pathology, University
Hospital Zürich, Zürich, Switzerland. 3Department of Pathology, University of
Erlangen, Erlangen, Germany. 4Urology Practice Prüner Gang, Kiel, Germany.
Authors’ contributions
IN designed experiments, performed experiments, interpreted results, drafted
manuscript. JSB designed experiments, performed experiments. LDA
conducted statistical analysis, critical revision to manuscript. PJW, AH, SB
provided TMA, critical revision to manuscript. JL conducted the clinical trial
and provided the clinical data, critical revision of the manuscript. TFØ
designed experiments, interpreted results and critical revision to manuscript.
KBD designed experiments, optimized IHC, analyzed TMAs, interpreted
results, and critical revision to manuscript
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 October 2010 Accepted: 14 April 2011
Published: 14 April 2011
Nordentoft et al. BMC Cancer 2011, 11:135
http://www.biomedcentral.com/1471-2407/11/135
Page 10 of 11
References
1. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet 2009,
374:239-249.
2. Vaishampayan U: Systemic therapy of advanced urothelial cancer. Curr
Treat Options Oncol 2009, 10:256-266.
3. Von Der MH, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al:
Long-term survival results of a randomized trial comparing gemcitabine
plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin
in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
4. Von Der MH, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al:
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin,
and cisplatin in advanced or metastatic bladder cancer: results of a
large, randomized, multinational, multicenter, phase III study. J Clin Oncol
2000, 18:3068-3077.
5. Als AB, Dyrskjot L, Von Der MH, Koed K, Mansilla F, Toldbod HE, et al:
Emmprin and survivin predict response and survival following cisplatin-
containing chemotherapy in patients with advanced bladder cancer. Clin
Cancer Res 2007, 13:4407-4414.
6. Eckert D, Buhl S, Weber S, Jager R, Schorle H: The AP-2 family of
transcription factors. Genome Biol 2005, 6:246.
7. Pellikainen JM, Kosma VM: Activator protein-2 in carcinogenesis with a
special reference to breast cancer–a mini review. Int J Cancer 2007,
120:2061-2067.
8. Brewer S, Williams T: Loss of AP-2alpha impacts multiple aspects of
ventral body wall development and closure. Dev Biol 2004, 267:399-417.
9. Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S: Identification of novel
deletion regions on chromosome arms 2q and 6p in breast carcinomas
by amplotype analysis. Genes Chromosomes Cancer 2001, 30:113-122.
10. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM,
et al: Automated quantitative analysis of activator protein-2alpha
subcellular expression in melanoma tissue microarrays correlates with
survival prediction. Cancer Res 2005, 65:11185-11192.
11. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM,
et al: Expression of transcription factor AP-2 in colorectal adenomas and
adenocarcinomas; comparison of immunohistochemistry and in situ
hybridisation. J Clin Pathol 2001, 54:533-538.
12. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V,
Kellokoski J, et al: Expression of HER2 and its association with AP-2 in
breast cancer. Eur J Cancer 2004, 40:1485-1495.
13. Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, et al:
Expression of transcription factor AP-2alpha predicts survival in
epithelial ovarian cancer. Br J Cancer 2000, 82:1974-1983.
14. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, et al: Loss
of the AP-2alpha transcription factor is associated with the grade of
human gliomas. Clin Cancer Res 2005, 11:267-272.
15. Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M, Kosma V: Expression of
activator protein 2 in prostate cancer is related to tumor differentiation
and cell proliferation. Eur Urol 2000, 37:573-578.
16. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC:
Immunohistochemical analysis reveals a tumour suppressor-like role for
the transcription factor AP-2 in invasive breast cancer. J Pathol 1999,
189:514-520.
17. Bar-Eli M: Gene regulation in melanoma progression by the AP-2
transcription factor. Pigment Cell Res 2001, 14:78-85.
18. Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C, et al: Adjuvant
cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin,
and cisplatin in locally advanced bladder cancer: results of a
randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005,
23:4963-4974.
19. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, et al:
MDR1 and ERCC1 expression predict outcome of patients with locally
advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia
2010, 12:628-636.
20. Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F,
et al: Simultaneous detection of HER2/neu gene amplification and
protein overexpression in paraffin-embedded breast cancer. J Pathol
2005, 205:577-584.
21. Andersen CL, Jensen JL, Orntoft TF: Normalization of real-time
quantitative reverse transcription-PCR data: a model-based variance
estimation approach to identify genes suited for normalization, applied
to bladder and colon cancer data sets. Cancer Res 2004, 64:5245-5250.
22. Birkenkamp-Demtroder K, Wagner L, Brandt SF, Bording AL, Gartner W,
Scherubl H, et al: Secretagogin is a novel marker for neuroendocrine
differentiation. Neuroendocrinology 2005, 82:121-138.
23. McPherson LA, Loktev AV, Weigel RJ: Tumor suppressor activity of
AP2alpha mediated through a direct interaction with p53. J Biol Chem
2002, 277:45028-45033.
24. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM:
Downregulation of transcription factor AP-2 predicts poor survival in
stage I cutaneous malignant melanoma. J Clin Oncol 1998, 16:3584-3591.
25. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V,
Kellokoski J, et al: Expression of HER2 and its association with AP-2 in
breast cancer. Eur J Cancer 2004, 40:1485-1495.
26. Wajapeyee N, Raut CG, Somasundaram K: Activator protein 2alpha status
determines the chemosensitivity of cancer cells: implications in cancer
chemotherapy. Cancer Res 2005, 65:8628-8634.
27. Kyriazis AP, Kyriazis AA, McCombs WB III, Kereiakes JA: Biological behavior
of human malignant tumors grown in the nude mouse. Cancer Res 1981,
41:3995-4000.
28. Kyriazis AA, Kyriazis AP, McCombs WB III, Peterson WD Jr: Morphological,
biological, and biochemical characteristics of human bladder transitional
cell carcinomas grown in tissue culture and in nude mice. Cancer Res
1984, 44:3997-4005.
29. Zeng YX, Somasundaram K, el-Deiry WS: AP2 inhibits cancer cell growth
and activates p21WAF1/CIP1 expression. Nat Genet 1997, 15:78-82.
30. Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De BM, et al: p53-
dependent downregulation of metastasis-associated laminin receptor.
Oncogene 2002, 21:7478-7487.
31. Wajapeyee N, Somasundaram K: Cell cycle arrest and apoptosis induction
by activator protein 2alpha (AP-2alpha) and the role of p53 and
p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J Biol Chem
2003, 278:52093-52101.
32. Orso F, Penna E, Cimino D, Astanina E, Maione F, Valdembri D, et al: AP-
2alpha and AP-2gamma regulate tumor progression via specific genetic
programs. FASEB J 2008, 22:2702-2714.
33. Mohamed S, Yasufuku K, Nakajima T, Hiroshima K, Kubo R, Iyoda A, et al:
Analysis of cell cycle-related proteins in mediastinal lymph nodes of
patients with N2-NSCLC obtained by EBUS-TBNA: relevance to
chemotherapy response. Thorax 2008, 63:642-647.
34. Karamitopoulou E, Zlobec I, Patsouris E, Peros G, Lugli A: Loss of E-cadherin
independently predicts the lymph node status in colorectal cancer.
Pathology 2011, 43:133-137.
35. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ,
et al: Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9
and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene
2007, 26:4049-4058.
36. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L,
Abbruzzese JL, et al: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res 2009, 69:5820-5828.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/135/prepub
doi:10.1186/1471-2407-11-135
Cite this article as: Nordentoft et al.: Increased expression of
transcription factor TFAP2a correlates with chemosensitivity in
advanced bladder cancer. BMC Cancer 2011 11:135.
Nordentoft et al. BMC Cancer 2011, 11:135
http://www.biomedcentral.com/1471-2407/11/135
Page 11 of 11
